Sign in to view content

One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa

Benjamin Bakall, MD, PhD

Video
Published 2024

Related

One Year Follow-Up in a Phase ½ Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Updates from the Field
2024
BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)
Michael A. Singer, MD
Updates from the Field
2024

Category: Hereditary Retinal Disease & Genetics

See more